AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Abeona Therapeutics Inc.

$5.42 +$0.11 (+1.98%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$5.48
Day Range
$5.4$5.61
Year Range
$4$7.65
Market Cap
308.63M
AVG Volume
1.33M
Trailing/Forward PE
-4.77/-
PEG ratio
0.06
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD)
05M10M15M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q211.38M
26 Q18.72M
25 Q45.42M
25 Q30
25 Q2400K
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
Net Income (USD)
-50M050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-20.19M
26 Q1-17.07M
25 Q4-20.46M
25 Q3-5.16M
25 Q2108.83M
25 Q1-12.03M
24 Q4-9.29M
24 Q3-30.27M
24 Q27.41M
24 Q1-31.58M
Operating Income (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-13.65M
26 Q1-23.03M
25 Q4-22.91M
25 Q3-24.02M
25 Q2-22.79M
25 Q1-19.73M
24 Q4-16.67M
24 Q3-15.35M
24 Q2-17.86M
24 Q1-14.33M
EBITDA (USD)
-50M050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-18.8M
26 Q1-15.37M
25 Q4-18.7M
25 Q3-18.57M
25 Q2126.07M
25 Q1-10.22M
24 Q4-7.44M
24 Q3-28.45M
24 Q29.16M
24 Q1-29.9M
Cash Flows (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-17.98M
26 Q1-20.74M
25 Q4-19.11M
25 Q3-23.71M
25 Q2-21.68M
25 Q1-19.8M
24 Q4-17.16M
24 Q3-12.64M
24 Q2-13.39M
24 Q1-15.26M
EPS (USD)
-2-101224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.35
26 Q1-0.3
25 Q4-0.36
25 Q3-0.1
25 Q21.71
25 Q1-0.24
24 Q4-0.23
24 Q3-0.63
24 Q20.14
24 Q1-1.16
Expenses (USD)
010M20M30MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q221.34M
26 Q129.12M
25 Q426.65M
25 Q326.05M
25 Q225.99M
25 Q121.13M
24 Q416.5M
24 Q315.75M
24 Q218.57M
24 Q115.05M
Cash & Debt (USD)
0100M200M300MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q2146.83M
26 Q1168.27M
25 Q4191.4M
25 Q3207.46M
25 Q2225.52M
25 Q184.16M
24 Q497.72M
24 Q3109.7M
24 Q2122.71M
24 Q162.34M
Debt ratios
-4-202424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Debt ratios by quarter
PeriodDebt ratios
26 Q21.78
26 Q1-1.98
25 Q4-2.12
25 Q3-2.04
25 Q2-2.52
25 Q11.63
24 Q41.32
24 Q31.33
24 Q22.1
24 Q10.54
Margins
-10000%-7500%-5000%-2500%0%2500%20 Q421 Q422 Q122 Q222 Q423 Q225 Q225 Q426 Q126 Q2
ABEO Margins by quarter
PeriodMargins
26 Q263.3%
26 Q159.12%
25 Q447.66%
25 Q275%
23 Q255%
22 Q4-9270.59%
22 Q2-600.8%
22 Q1-2947.69%
21 Q4-326.77%
20 Q4100%
Return on Capital
-200%0%200%400%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Return on Capital by quarter
PeriodReturn on Capital
26 Q2-15.77%
26 Q1-11.78%
25 Q4-12.85%
25 Q3-3.01%
25 Q266.53%
25 Q1-29.06%
24 Q4-21.11%
24 Q3-66.13%
24 Q210.11%
24 Q1355.57%
Shares Outstanding
020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Shares Outstanding by quarter
PeriodShares Outstanding
26 Q257.05M
26 Q156.62M
25 Q452.95M
25 Q354.24M
25 Q252.52M
25 Q149.78M
24 Q441.05M
24 Q348.08M
24 Q240.01M
24 Q127.32M
Dividends (USD)
01000200030004000Mar 00
ABEO Dividends (USD) by quarter
PeriodDividends (USD)
Mar 003706.25
Employee Count
01002003002016201720182019202020212022202320242025
ABEO Employee Count by quarter
PeriodEmployee Count
2025226
2024136
202384
202257
202190
202076
201988
201883
201742
201619
Book Value Per Share (USD)
-10123424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q22.24
26 Q12.56
25 Q43.01
25 Q33.16
25 Q23.11
25 Q10.83
24 Q41.07
24 Q30.95
24 Q21.83
24 Q1-0.33
Total Assets (USD)
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ABEO Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q2179.51M
26 Q1198.49M
25 Q4219.57M
25 Q3231.09M
25 Q2246.23M
25 Q199.36M
24 Q4108.93M
24 Q3120.59M
24 Q2134M
24 Q174.83M
PE Ratio
234567med 4.24Sep 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
ABEO PE Ratio by quarter
PeriodPE Ratio
Aug 266.2
Jul 265.5
Jul 265.18
Jul 265.99
Jul 265.98
Jul 265.48
Jun 264.8
Jun 264.94
Jun 264.73
Jun 264.67
May 264.95
May 264.66
May 264.7
May 264.39
May 264.04
Apr 264.01
Apr 264.09
Apr 263.65
Apr 263.59
Mar 263.19
Mar 263.31
Mar 263.14
Mar 263.19
Feb 263.37
Feb 263.46
Feb 263.3
Feb 263.38
Jan 263.35
Jan 263.4
Jan 263.46
Jan 263.42
Jan 263.5
Dec 253.59
Dec 253.37
Dec 253.53
Dec 253.21
Nov 253.34
Nov 252.95
Nov 252.93
Nov 253.85
Oct 254.41
Oct 255.03
Oct 254.94
Oct 254.92
Oct 254.96
Sep 254.99
Sep 254.94
Sep 255.9
Sep 256.32
Aug 256.27
Aug 256.63
Aug 256.54
Free Cash Flow Yield
-40%-30%-20%-10%med -24.45%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ABEO Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-26.37%
Sep 26-23.82%
Aug 26-24.14%
Aug 26-23.47%
Aug 26-23.86%
Aug 26-20.79%
Jul 26-23.45%
Jul 26-24.88%
Jul 26-21.51%
Jul 26-21.57%
Jul 26-23.52%
Jun 26-26.83%
Jun 26-26.09%
Jun 26-27.22%
Jun 26-27.57%
May 26-26.04%
May 26-27.67%
May 26-27.42%
May 26-26.98%
May 26-29.32%
Apr 26-29.54%
Apr 26-28.95%
Apr 26-32.42%
Apr 26-33.03%
Mar 26-37.11%
Mar 26-35.78%
Mar 26-31.9%
Mar 26-31.31%
Feb 26-29.66%
Feb 26-28.87%
Feb 26-30.31%
Feb 26-29.6%
Jan 26-29.83%
Jan 26-29.43%
Jan 26-28.92%
Jan 26-29.26%
Jan 26-28.59%
Dec 25-27.86%
Dec 25-29.71%
Dec 25-28.33%
Dec 25-31.18%
Nov 25-29.95%
Nov 25-33.89%
Nov 25-34.12%
Nov 25-32.32%
Oct 25-28.22%
Oct 25-24.77%
Oct 25-25.23%
Oct 25-25.32%
Oct 25-25.09%
Sep 25-24.95%
Sep 25-25.23%
Sep 25-21.11%
Sep 25-19.7%
Aug 25-19.87%
Aug 25-18.77%
Aug 25-19.04%
Aug 25-20.22%
Aug 25-19.5%
Jul 25-19.38%
Jul 25-19.21%
Jul 25-22.05%
Jul 25-21.49%
Jun 25-22.01%
Jun 25-21.49%
Jun 25-20.55%
Jun 25-18.78%
May 25-20.28%
May 25-19.71%
May 25-20.75%
May 25-27.02%
May 25-21.71%
Apr 25-26.72%
Apr 25-29.43%
Apr 25-30.96%
Apr 25-31.51%
Mar 25-28.66%
Mar 25-27.65%
Mar 25-19.88%
Mar 25-20.38%
Feb 25-20.07%
Feb 25-18.2%
Feb 25-17.47%
Feb 25-18.45%
Jan 25-18.98%
Jan 25-19.99%
Jan 25-20.15%
Jan 25-18.95%
Jan 25-17.47%
Dec 24-18.68%
Dec 24-18.45%
Dec 24-17.86%
Dec 24-17.44%
Nov 24-16.46%
Nov 24-17.59%
Nov 24-17.95%
Nov 24-17.07%
Nov 24-17.48%
Oct 24-16.81%
Oct 24-16.38%
Price to Sales
02505007501000med 40.18Dec 23Apr 24Jul 24Oct 25Feb 26May 26Sep 26
ABEO Price to Sales by quarter
PeriodPrice to Sales
Sep 2612.12
Sep 2613.41
Aug 2613.23
Aug 2613.61
Aug 2613.39
Aug 2628.19
Jul 2625
Jul 2623.56
Jul 2627.26
Jul 2627.18
Jul 2624.92
Jun 2621.85
Jun 2622.47
Jun 2621.53
Jun 2621.26
May 2622.51
May 2621.18
May 2621.38
May 2653.68
May 2649.4
Apr 2649.04
Apr 2650.04
Apr 2644.67
Apr 2643.85
Mar 2639.03
Mar 2640.49
Mar 26645.49
Mar 26657.69
Feb 26694.3
Feb 26713.29
Feb 26679.39
Feb 26695.66
Jan 26690.24
Jan 26699.73
Jan 26711.93
Jan 26703.8
Jan 26720.07
Dec 25739.05
Dec 25692.95
Dec 25726.85
Dec 25660.4
Nov 25687.52
Nov 25607.52
Nov 25603.45
Nov 25551.51
Oct 25631.61
Oct 25719.59
Oct 25706.45
Oct 25703.83
Oct 25710.39
Sep 25714.33
Sep 25706.45
Sep 25844.33
Sep 25904.73
Aug 25896.86
Aug 25949.38
Aug 25936.25
Aug 2434.5
Aug 2436.68
Jul 2439.8
Jul 2439.88
Jul 2443
Jul 2435.43
Jun 2433.09
Jun 2435.74
Jun 2435.67
Jun 2433.33
May 2434.18
May 2431.69
May 2434.34
May 2430.67
May 2433.59
Apr 2423.8
Apr 2455.27
Apr 2455.13
Apr 2454.32
Mar 2452.94
Mar 2455.57
Mar 2459.98
Mar 2455.39
Mar 2454.28
Feb 2448.51
Feb 2448.72
Feb 2443.09
Feb 2430.72
Jan 2432.6
Jan 2434.75
Jan 2436.49
Jan 2439.34
Dec 2334.82
Dec 2334.54
Dec 2333.85
Dec 2333.22
Dec 2332.39
Nov 2329.95
Nov 2329.12
Nov 2320.65
Nov 2322.67
Oct 2318.74
Oct 2320.91
EV/EBITDA
01234med 1.15Sep 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
ABEO EV/EBITDA by quarter
PeriodEV/EBITDA
Aug 263.61
Jul 262.97
Jul 262.69
Jul 263.42
Jul 263.41
Jul 262.96
Jun 262.35
Jun 262.47
Jun 262.29
Jun 262.23
May 262.48
May 262.22
May 262.26
May 261.86
May 261.54
Apr 261.51
Apr 261.59
Apr 261.19
Apr 261.13
Mar 260.77
Mar 260.88
Mar 260.83
Mar 260.89
Feb 261.05
Feb 261.13
Feb 260.98
Feb 261.06
Jan 261.03
Jan 261.07
Jan 261.13
Jan 261.09
Jan 261.17
Dec 251.25
Dec 251.04
Dec 251.2
Dec 250.9
Nov 251.02
Nov 250.66
Nov 250.65
Nov 250.24
Oct 250.64
Oct 251.08
Oct 251.01
Oct 251
Oct 251.03
Sep 251.05
Sep 251.01
Sep 251.7
Sep 252.01
Aug 251.97
Aug 252.23
Aug 252.16
Price to Book
0246810med 2.57Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ABEO Price to Book by quarter
PeriodPrice to Book
Sep 262.41
Sep 262.67
Aug 262.64
Aug 262.71
Aug 262.67
Aug 262.83
Jul 262.51
Jul 262.36
Jul 262.73
Jul 262.73
Jul 262.5
Jun 262.19
Jun 262.25
Jun 262.16
Jun 262.13
May 262.26
May 262.13
May 262.14
May 261.96
May 261.81
Apr 261.79
Apr 261.83
Apr 261.63
Apr 261.6
Mar 261.43
Mar 261.48
Mar 261.51
Mar 261.54
Feb 261.62
Feb 261.67
Feb 261.59
Feb 261.63
Jan 261.61
Jan 261.63
Jan 261.66
Jan 261.64
Jan 261.68
Dec 251.73
Dec 251.62
Dec 251.7
Dec 251.54
Nov 251.61
Nov 251.42
Nov 251.41
Nov 251.35
Oct 251.54
Oct 251.76
Oct 251.73
Oct 251.72
Oct 251.74
Sep 251.75
Sep 251.73
Sep 252.06
Sep 252.21
Aug 252.19
Aug 252.32
Aug 252.29
Aug 257.53
Aug 257.8
Jul 257.85
Jul 257.92
Jul 256.9
Jul 257.08
Jun 256.91
Jun 257.08
Jun 257.41
Jun 258.1
May 257.5
May 257.72
May 257.34
May 254.91
May 256.12
Apr 254.97
Apr 254.51
Apr 254.29
Apr 254.21
Mar 254.63
Mar 254.8
Mar 255.56
Mar 255.42
Feb 255.5
Feb 256.07
Feb 256.32
Feb 255.99
Jan 255.82
Jan 255.53
Jan 255.48
Jan 255.83
Jan 256.32
Dec 245.91
Dec 245.99
Dec 246.19
Dec 246.33
Nov 246.71
Nov 246.28
Nov 246.16
Nov 243.5
Nov 243.41
Oct 243.55
Oct 243.64
Abeona Therapeutics Inc.
ABEO
Stockpicker

Video analysis: ABEO

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

prnewswire.com · 10 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

businesswire.com · 8 Sep 2026

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

gurufocus.com · 8 Sep 2026

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

globenewswire.com · 8 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

globenewswire.com · 2 Sep 2026

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 1 Sep 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.